Showing results (161-170 of 250) with videos related to
Sort By:
Pageof 25
Diagnostics (Basel, Switzerland)|August 29, 2024
Polygenic Risk Score (PRS) Combined with NGS Panel Testing Increases Accuracy in Hereditary Breast Cancer Risk EstimationNikolaos Tsoulos, Eirini Papadopoulou, Konstantinos Agiannitopoulos, et al.Anticancer Research|April 30, 2016
Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast CancerSotirios Lakis, Stefanos Dimoudis, Vassiliki Kotoula, et al.Lancet (London, England)|June 15, 2020
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialRalf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, et al.Journal of Translational Medicine|May 30, 2015
Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation studyAngelos Koutras, Konstantine T Kalogeras, Ralph M Wirtz, et al.Translational Oncology|July 1, 2017
Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant ChemotherapyEleni Timotheadou, Konstantine T Kalogeras, Georgia-Angeliki Koliou, et al.Cancer Genomics & Proteomics|February 29, 2020
Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast CancerAdamantia Nikolaidi, Vassiliki Kotoula, Georgia-Angeliki Koliou, et al.Cancer Genomics & Proteomics|April 26, 2019
Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast CancerGeorgios Lazaridis, Vassiliki Kotoula, Eleni Vrettou, et al.The Lancet. Oncology|December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyPaolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.Cancers|June 2, 2021
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)Victoria G Atkinson, Pietro Quaglino, Massimo Aglietta, et al.Journal of Translational Medicine|May 18, 2016
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancerHelen Gogas, Vassiliki Kotoula, Zoi Alexopoulou, et al.Pageof 25